Date Posted: Wednesday, January 08, 2025

 

The Centers for Medicare & Medicaid Services (CMS) issued the Healthcare Common Procedure Coding System (HCPCS) J-code J9028 for billing and reimbursement of nogapendekin alfa inbakicept-pmln (Anktiva; N-803), as announced by ImmunityBio in a recent press release.

 

Approval and Application of Anktiva

 

Anktiva received FDA approval in April 2024 for use in combination with BCG to treat patients with BCG-unresponsive non–muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. The newly issued J-code for Anktiva became effective on January 1, 2025. This code is expected to simplify the billing and reimbursement process for healthcare providers administering this therapy.

 

“The unique J-code for Anktiva is another milestone in our quest to deliver the next generation of immunotherapy beyond T cell activation and enables patients with bladder cancer to benefit from the power of natural killer (NK) cells,” said Patrick Soon-Shiong, MD, Founder, Executive Chairman, and Global Chief Scientific and Medical Officer of ImmunityBio.

 

Importance of J-Codes

 

According to ImmunityBio, J-codes are essential tools for streamlining the billing and reimbursement process for intravesical therapies and certain other treatments. These unique identifiers are used by both government and commercial payors, as well as by healthcare providers and office staff.

 

Source: Urology Times

urologytimes.com

 

 

Have feedback or questions on this article? Get in touch with us directly. Email info@billing-coding.com.